Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 39 entries
Sorted by: Best Match Show Resources per page
How much do clinical trials cost?.

Nature reviews. Drug discovery

Martin L, Hutchens M, Hawkins C, Radnov A.
PMID: 28529317
Nat Rev Drug Discov. 2017 Jun;16(6):381-382. doi: 10.1038/nrd.2017.70. Epub 2017 May 19.

No abstract available.

Cite
Martin L, Hutchens M, Hawkins C, et al. How much do clinical trials cost?. Nat Rev Drug Discov. 2017;16(6):381-382doi: 10.1038/nrd.2017.70.
Martin, L., Hutchens, M., Hawkins, C., & Radnov, A. (2017). How much do clinical trials cost?. Nature reviews. Drug discovery, 16(6), 381-382. https://doi.org/10.1038/nrd.2017.70
Martin, Linda, et al. "How much do clinical trials cost?." Nature reviews. Drug discovery vol. 16,6 (2017): 381-382. doi: https://doi.org/10.1038/nrd.2017.70
Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost?. Nat Rev Drug Discov. 2017 Jun;16(6):381-382. doi: 10.1038/nrd.2017.70. Epub 2017 May 19. PMID: 28529317.
Copy Download .nbib Format: NLM
Improving Global Access to State of the Art Practice Information.

Journal of the American College of Radiology : JACR

Gilada TI, Baheti AD, Green DE.
PMID: 27451117
J Am Coll Radiol. 2016 Sep;13(9):1156-7. doi: 10.1016/j.jacr.2016.05.021. Epub 2016 Jul 19.

No abstract available.

Cite
Gilada TI, Baheti AD, Green DE. Improving Global Access to State of the Art Practice Information. J Am Coll Radiol. 2016;13(9):1156-7doi: 10.1016/j.jacr.2016.05.021.
Gilada, T. I., Baheti, A. D., & Green, D. E. (2016). Improving Global Access to State of the Art Practice Information. Journal of the American College of Radiology : JACR, 13(9), 1156-7. https://doi.org/10.1016/j.jacr.2016.05.021
Gilada, Trupti I, et al. "Improving Global Access to State of the Art Practice Information." Journal of the American College of Radiology : JACR vol. 13,9 (2016): 1156-7. doi: https://doi.org/10.1016/j.jacr.2016.05.021
Gilada TI, Baheti AD, Green DE. Improving Global Access to State of the Art Practice Information. J Am Coll Radiol. 2016 Sep;13(9):1156-7. doi: 10.1016/j.jacr.2016.05.021. Epub 2016 Jul 19. PMID: 27451117.
Copy Download .nbib Format: NLM
European collaboration on relative effectiveness will move into the next phase.

Journal of comparative effectiveness research

Goettsch W.
PMID: 24236514
J Comp Eff Res. 2013 Jan;2(1):5-6. doi: 10.2217/cer.12.70.

No abstract available.

Cite
Goettsch W. European collaboration on relative effectiveness will move into the next phase. J Comp Eff Res. 2013;2(1):5-6doi: 10.2217/cer.12.70.
Goettsch, W. (2013). European collaboration on relative effectiveness will move into the next phase. Journal of comparative effectiveness research, 2(1), 5-6. https://doi.org/10.2217/cer.12.70
Goettsch, Wim. "European collaboration on relative effectiveness will move into the next phase." Journal of comparative effectiveness research vol. 2,1 (2013): 5-6. doi: https://doi.org/10.2217/cer.12.70
Goettsch W. European collaboration on relative effectiveness will move into the next phase. J Comp Eff Res. 2013 Jan;2(1):5-6. doi: 10.2217/cer.12.70. PMID: 24236514.
Copy Download .nbib Format: NLM
Economic lessons in the land of plenty.

The Journal of the Oklahoma State Medical Association

Pontious JM.
PMID: 23795522
J Okla State Med Assoc. 2013 Apr;106(4):123-4.

No abstract available.

Cite
Pontious JM. Economic lessons in the land of plenty. J Okla State Med Assoc. 2013;106(4):123-4
Pontious, J. M. (2013). Economic lessons in the land of plenty. The Journal of the Oklahoma State Medical Association, 106(4), 123-4.
Pontious, J Michael. "Economic lessons in the land of plenty." The Journal of the Oklahoma State Medical Association vol. 106,4 (2013): 123-4.
Pontious JM. Economic lessons in the land of plenty. J Okla State Med Assoc. 2013 Apr;106(4):123-4. PMID: 23795522.
Copy Download .nbib Format: NLM
High throughput in drug discovery.

Drug discovery today

Kubinyi H.
PMID: 12110225
Drug Discov Today. 2002 Jul 01;7(13):707-9. doi: 10.1016/s1359-6446(02)02323-1.

No abstract available.

Cite
Kubinyi H. High throughput in drug discovery. Drug Discov Today. 2002;7(13):707-9doi: 10.1016/s1359-6446(02)02323-1.
Kubinyi, H. (2002). High throughput in drug discovery. Drug discovery today, 7(13), 707-9. https://doi.org/10.1016/s1359-6446(02)02323-1
Kubinyi, Hugo. "High throughput in drug discovery." Drug discovery today vol. 7,13 (2002): 707-9. doi: https://doi.org/10.1016/s1359-6446(02)02323-1
Kubinyi H. High throughput in drug discovery. Drug Discov Today. 2002 Jul 01;7(13):707-9. doi: 10.1016/s1359-6446(02)02323-1. PMID: 12110225.
Copy Download .nbib Format: NLM
Poor nations push for right to produce cheap medicines.

Nature

Goodman S.
PMID: 11429562
Nature. 2001 Jun 28;411(6841):982. doi: 10.1038/35082723.

No abstract available.

Cite
Goodman S. Poor nations push for right to produce cheap medicines. Nature. 2001;411(6841):982doi: 10.1038/35082723.
Goodman, S. (2001). Poor nations push for right to produce cheap medicines. Nature, 411(6841), 982. https://doi.org/10.1038/35082723
Goodman, S. "Poor nations push for right to produce cheap medicines." Nature vol. 411,6841 (2001): 982. doi: https://doi.org/10.1038/35082723
Goodman S. Poor nations push for right to produce cheap medicines. Nature. 2001 Jun 28;411(6841):982. doi: 10.1038/35082723. PMID: 11429562.
Copy Download .nbib Format: NLM
US drug sales continue to rise.

BMJ (Clinical research ed.)

Gottlieb S.
PMID: 12623895
BMJ. 2003 Mar 08;326(7388):518. doi: 10.1136/bmj.326.7388.518/c.

No abstract available.

Cite
Gottlieb S. US drug sales continue to rise. BMJ. 2003;326(7388):518doi: 10.1136/bmj.326.7388.518/c.
Gottlieb, S. (2003). US drug sales continue to rise. BMJ (Clinical research ed.), 326(7388), 518. https://doi.org/10.1136/bmj.326.7388.518/c
Gottlieb, Scott. "US drug sales continue to rise." BMJ (Clinical research ed.) vol. 326,7388 (2003): 518. doi: https://doi.org/10.1136/bmj.326.7388.518/c
Gottlieb S. US drug sales continue to rise. BMJ. 2003 Mar 08;326(7388):518. doi: 10.1136/bmj.326.7388.518/c. PMID: 12623895; PMCID: PMC1169281.
Copy Download .nbib Format: NLM
Review of drug subsidy scheme delayed as test case looms.

BMJ (Clinical research ed.)

Burton B.
PMID: 17170409
BMJ. 2006 Dec 16;333(7581):1239. doi: 10.1136/bmj.39062.420995.DB.

No abstract available.

Cite
Burton B. Review of drug subsidy scheme delayed as test case looms. BMJ. 2006;333(7581):1239doi: 10.1136/bmj.39062.420995.DB.
Burton, B. (2006). Review of drug subsidy scheme delayed as test case looms. BMJ (Clinical research ed.), 333(7581), 1239. https://doi.org/10.1136/bmj.39062.420995.DB
Burton, Bob. "Review of drug subsidy scheme delayed as test case looms." BMJ (Clinical research ed.) vol. 333,7581 (2006): 1239. doi: https://doi.org/10.1136/bmj.39062.420995.DB
Burton B. Review of drug subsidy scheme delayed as test case looms. BMJ. 2006 Dec 16;333(7581):1239. doi: 10.1136/bmj.39062.420995.DB. PMID: 17170409; PMCID: PMC1702483.
Copy Download .nbib Format: NLM
Better measures of affordability required.

Lancet (London, England)

Niëns LM, Brouwer WB.
PMID: 19329001
Lancet. 2009 Mar 28;373(9669):1081; author reply 1081-2. doi: 10.1016/S0140-6736(09)60649-8.

No abstract available.

Cite
Niëns LM, Brouwer WB. Better measures of affordability required. Lancet. 2009;373(9669):1081; author reply 1081-2doi: 10.1016/S0140-6736(09)60649-8.
Niëns, L. M., & Brouwer, W. B. (2009). Better measures of affordability required. Lancet (London, England), 373(9669), 1081; author reply 1081-2. https://doi.org/10.1016/S0140-6736(09)60649-8
Niëns, L M, and Brouwer, W B F. "Better measures of affordability required." Lancet (London, England) vol. 373,9669 (2009): 1081; author reply 1081-2. doi: https://doi.org/10.1016/S0140-6736(09)60649-8
Niëns LM, Brouwer WB. Better measures of affordability required. Lancet. 2009 Mar 28;373(9669):1081; author reply 1081-2. doi: 10.1016/S0140-6736(09)60649-8. PMID: 19329001.
Copy Download .nbib Format: NLM
[Consumption of medical services and the economics of health].

La Revue du praticien

Le Faou AL.
PMID: 19894457
Rev Prat. 2009 Oct 20;59(8):1123-4.

No abstract available.

Cite
Le Faou AL. Protection sociale consommation médicale et économie de santé. 1re Partie--Consommation médicale et économie de sante. [Consumption of medical services and the economics of health]. Rev Prat. 2009;59(8):1123-4
Le Faou, A. L. (2009). Protection sociale consommation médicale et économie de santé. 1re Partie--Consommation médicale et économie de sante. [Consumption of medical services and the economics of health]. La Revue du praticien, 59(8), 1123-4.
Le Faou, Anne-Laurence. "Protection sociale consommation médicale et économie de santé. 1re Partie--Consommation médicale et économie de sante." [Consumption of medical services and the economics of health]. La Revue du praticien vol. 59,8 (2009): 1123-4.
Le Faou AL. Protection sociale consommation médicale et économie de santé. 1re Partie--Consommation médicale et économie de sante. [Consumption of medical services and the economics of health]. Rev Prat. 2009 Oct 20;59(8):1123-4. French. PMID: 19894457.
Copy Download .nbib Format: NLM
Analysis of pharmaceutical product diversion and the gray market: cheaper drugs, but at what cost?.

Health care law monthly

Dooley K, Sullivan JA.
PMID: 21302589
Health Care Law Mon. 2010 Oct;2010(10):2-8.

No abstract available.

Cite
Dooley K, Sullivan JA. Analysis of pharmaceutical product diversion and the gray market: cheaper drugs, but at what cost?. Health Care Law Mon. 2010;2010(10):2-8
Dooley, K., & Sullivan, J. A. (2010). Analysis of pharmaceutical product diversion and the gray market: cheaper drugs, but at what cost?. Health care law monthly, 2010(10), 2-8.
Dooley, Kathleen, and Sullivan, Julie Ann. "Analysis of pharmaceutical product diversion and the gray market: cheaper drugs, but at what cost?." Health care law monthly vol. 2010,10 (2010): 2-8.
Dooley K, Sullivan JA. Analysis of pharmaceutical product diversion and the gray market: cheaper drugs, but at what cost?. Health Care Law Mon. 2010 Oct;2010(10):2-8. PMID: 21302589.
Copy Download .nbib Format: NLM
Combating inappropriate use of medicines.

Expert review of clinical pharmacology

Holloway KA.
PMID: 22114780
Expert Rev Clin Pharmacol. 2011 May;4(3):335-48. doi: 10.1586/ecp.11.14.

Globally, it is possible that less than half of all patients are treated in compliance with guidelines and more than half of all patients fail to take their medicines as prescribed or dispensed. Such inappropriate use is wasteful of...

Cite
Holloway KA. Combating inappropriate use of medicines. Expert Rev Clin Pharmacol. 2011;4(3):335-48doi: 10.1586/ecp.11.14.
Holloway, K. A. (2011). Combating inappropriate use of medicines. Expert review of clinical pharmacology, 4(3), 335-48. https://doi.org/10.1586/ecp.11.14
Holloway, Kathleen Anne. "Combating inappropriate use of medicines." Expert review of clinical pharmacology vol. 4,3 (2011): 335-48. doi: https://doi.org/10.1586/ecp.11.14
Holloway KA. Combating inappropriate use of medicines. Expert Rev Clin Pharmacol. 2011 May;4(3):335-48. doi: 10.1586/ecp.11.14. PMID: 22114780.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 39 entries